Concepedia

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics

Erica L. Mayer, Steven J. Isakoff, Giannoula Klement, Sean R. Downing, Wendy Y. Chen, Keri Hannagan, Rebecca Gelman, Eric P. Winer, Harold J. Burstein

Breast Cancer Research and Treatment · 2012 · 44 citations · 48 references

DOIFull text

Open access

Concepts

References

48

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 11K citations · Full text

, , +15

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

, , +13

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Timothy M. Browder, Catherine Butterfield, Birgit M. Kräling et al. · PubMed · 2000 · 1.6K citations

, , +16

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2011 · 1.6K citations · Full text

, , +6